It is well established that patients with type-2 diabetes have a higher risk of cardiovascular complications. An exploratory analysis of the DAPA-HF trial data reveals that dapagliflozin treatment is associated with a significant reduction in the risk of cardiovascular death.
The increased benefits of dapagliflozin have put the dapagliflozin manufacturer in India at the forefront. While cardiovascular disease remains the leading cause of death, the approval of multiple novel glucose-lowering agents has provided clinicians with various treatment options. Type 2 diabetes mellitus (T2DM) is a global epidemic that affects over 450 million adults and is increasing healthcare expenditures.
Multiple cardiovascular outcome trials (CVOTs) conduct to clarify the effect of novel anti-diabetic agents on significant cardiovascular endpoints. While improved glycemic control is associated with beneficial effects on microvascular outcomes, the result on cardiovascular endpoints has no conclusion.
As a result, pharma contract manufacturers in India recommend that the selection of an anti-diabetic medication should not solely be based on the possibility of improved glycemic control but also on the capability of antihyperglycemic medications to provide cardiovascular benefits.
The study included people who had diabetes and people who had heart failure that was getting worse and were either treated in a hospital or an outpatient setting. Additionally, individuals included had echocardiogram (ECG) values at enrollment that were higher than or equal to 40%.
Effects of Dapagliflozin on Men and Women
Due to sex-related differences in pharmacy kinetics and dynamics, women respond differently to specific treatments than men.
Other studies have shown that cardiac resynchronization therapy reduces women’s risk of all-cause death, cardiovascular death, death or heart failure hospitalization, ventricular arrhythmias or sudden cardiac death more than men do. Such studies help top CDMO companies in India to manufacture more affordable medications for the masses.
Because of these differences, it is critical to determine whether or not new heart failure treatments are safe and effective for both men and women. Additionally, there has been some debate regarding the gender-specific effects of SGLT2 inhibitors; In particular, women with diabetes appear to have a lower reduction in cardiovascular death and death from any cause with SGLT2 inhibitors in cardiovascular outcome trials than men.
Dapagliflozin manufacturers in India say that the drug reduced the primary outcome of a worsening HF event or cardiovascular death in men and women in this prespecified subgroup analysis of DAPA-HF. Additionally, regardless of sex, dapagliflozin consistently outperformed other clinical endpoints, such as first- and recurrent HF hospitalization, cardiovascular death, and all-cause death. In an optimally treated cohort of patients with HFrEF, these data demonstrate the clinically significant benefits of dapagliflozin, regardless of sex.
Women and men experienced similar effects of dapagliflozin on eGFR, body weight, systolic blood pressure, and hematocrit. In this regard, it is crucial to note that women had comparable clinical benefits despite having worse kidney function than men at baseline, which should have reduced glucosuria and diuresis.
Dapagliflozin improves both men’s and women’s symptoms, physical function, and health-related quality of life and decreases the risk of worsening HF events, cardiovascular death, and all-cause death.
The rewarding research results prove that dapagliflozin is a miracle medicine that improves morbidity and reduces the risk of death in cases of heart failure.
The studies may produce positive outcomes if they have more supporting data. Clinics are always looking for a dependable producer of pharmaceuticals. Pinnacle, a pharma contract manufacturer in India, is ready to provide something meaningful yet beneficial for the masses. We are always looking for ways to make a healthier world.